# US 11,998,001 B2 · Perfusion device for normothermic, ex vivo preservation of a mammalian brain > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,998,001 B2 - Document ID: US11998001B2 - Status: Granted - Kind: B2 - Application number: 16/967,925 - Filed: 2019-02-08 - Published: 2021-11-25 - Granted: 2024-06-04 - Earliest claimed: 2018-02-09 - Assignees: Yale University - Applicants: Yale University - Inventors: Stefano Daniele; Nenad Sestan; John Silbereis; Zvonimir Vrselja - Web page: https://patentgrep.com/patent/US11998001B2 ## CPC - A01N 1/122: Preservation or perfusion media - A01N 1/143: for organ perfusion - A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS ## Abstract The invention provides a system for normothermic, ex vivo restoration and preservation of an intact mammalian brain, and other organs. In certain aspects, the system is capable of preserving a brain as well as other organs, maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides synthetic brain perfusate formulations, including a novel brain perfusion medium (BPM), which are able to reduce reperfusion injury, stimulate recovery from hypoxia, prevent edema and metabolically support the energy needs of brain function. ## Claims ### Claim 1 A perfusion device for the normothermic, ex vivo preservation of a mammalian brain, the device comprising: a perfusion loop comprising a filtration loop having at least one hemodiafiltration unit adapted and configured to remove metabolic toxins from and add nutrients to a perfusate; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain normothermic conditions; and a brain enclosure unit adapted and configured to receive and house a mammalian brain; and a heat exchange unit adapted and configured to regulate the temperature of the brain enclosure unit and the perfusion loop; wherein the perfusion loop is adapted and configured to oxygenate/carboxygenate the perfusate and circulate the perfusate through the brain contained within the brain enclosure unit; and wherein, the perfusate comprises: a culture medium comprising glucose, one or more amino acids, one or more water soluble salts and one more vitamins; one or more artificial oxygen carrier compounds; and one or more compounds selected from the group consisting of anti-cytotoxic compounds, antioxidants, anti-necrotic compounds, antiexcitotoxic compounds, anti-inflammatory compounds, antiepileptic compounds, anti-apoptotic compounds, antibiotics, cell death inhibitors, neuroprotectants and oxidative/nitrosative stress inhibitors. ### Claim 2 (depends on 1) The device of claim 1, wherein the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop. ### Claim 3 (depends on 2) The device of claim 2, wherein the mammalian brain is a brain from a source selected from the group consisting of murine, canine, ovine, porcine, bovine and primate sources. ### Claim 4 (depends on 3) The device of claim 3, wherein the mammalian brain is a human brain. ### Claim 5 (depends on 3) The device of claim 3, wherein the mammalian brain is maintained ex cranio. ### Claim 6 (depends on 2) The device of claim 2, wherein the device perfuses the brain with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute. ### Claim 7 (depends on 1) The device of claim 1, wherein the perfusion loop further comprises a venous loop, and an arterial loop along with the filtration loop, wherein: the venous loop comprises at least one perfusion pump; the filtration loop comprises at least one perfusion pump; the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate; wherein the brain enclosure unit, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the brain enclosure unit, through the venous loop, through the filtration loop, through the arterial loop and back to the brain enclosure unit. ### Claim 8 (depends on 7) The device of claim 7, wherein one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate. ### Claim 9 (depends on 7) The device of claim 7, wherein one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate. ### Claim 10 (depends on 9) The device of claim 9, wherein the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine. ### Claim 11 (depends on 9) The device of claim 9, wherein the device comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pressure and flow rate. ### Claim 12 (depends on 7) The device of claim 7, wherein one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps. ### Claim 13 (depends on 12) The device of claim 12, wherein the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device. ### Claim 14 (depends on 13) The device of claim 13, wherein the one or more sensors adapted and configured to measure the temperature within the perfusion device, the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device. ### Claim 15 (depends on 1) The device of claim 1, wherein the hemodiafiltration unit is adapted and configured to remove one or more metabolic toxins from the perfusate selected from the group consisting of water, lactate, dissolved gases, ammonia, atrial natriuretic peptide, β2-microglobulin, β-endorphin, cholecystokinin, Clara cell protein, creatinine complement factor D, cystatin C, degranulation inhibitor protein, delta sleep-inducing peptide, endothelin, glutamate, hyaluronic acid, IL-1α, IL-6, κ-Ig light chain, λ-Ig light chain, neuropeptide Y, retinol-binding protein, tumor necrosis factor-α, uric acid, urea, IFN-γ, IL-1β, IL-18, and glutamate. ### Claim 16 (depends on 1) The device of claim 1, wherein the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L-Alanyl-Glutamine, L-Arginine hydrochloride, L-Cystine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Vitamins, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i-Inositol, Inorganic Salts, Calcium Chloride (CaCl2)-2H2O), Ferric Nitrate (Fe(NO3)3 9H2O), Magnesium Sulfate (MgSO4-7H2O), Potassium Chloride (KCl), Sodium Bicarbonate (NaHCO3), Sodium Chloride (NaCl), Sodium Phosphate monobasic (NaH2PO4-2H2O), D-Glucose, Phenol Red, Sodium Pyruvate, free fatty acids, and cholesterol. ### Claim 17 (depends on 1) The device of claim 1, wherein the device is mounted on a movable housing. ### Claim 18 (depends on 1) The device of claim 1, wherein the device perfuses the brain with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg. ### Claim 19 (depends on 1) The device of claim 1, further comprising a computer in electronic communication with one or more elements of the device. ### Claim 20 (depends on 1) A method for preparing an intact mammalian brain under normothermic, ex vivo conditions, the method comprising: isolating and cannulating the bilateral common carotid arteries; flushing the brain with a heparinized saline solution through the arteries to remove blood; optionally storing the brain on ice for a period of time; isolating the bilateral external carotid arteries, internal carotid arteries, occipital arteries, ophthalmic, vertebral, basilar, along with other smaller branches serving the brain; ligating all arteries except for the internal carotid artery to prevent vascular shunting and to selectively perfuse the brain; surgically removing the excess tissue from the skull while rendering the arteries undamaged; surgically removing the cranium from the brain to render the brain ex cranio for experimental manipulation; connecting the free-end arteries to the perfusion device of claim 1. ### Claim 21 (depends on 20) The method of claim 20, further comprising administering to the brain a composition comprising one or more vasoactive compounds. ### Claim 22 (depends on 21) The method of claim 21, wherein the one more vasoactive compounds are selected from the group consisting of nimodipine, irsadipine, nifedipine, nitrendipine, amlodipine, flunarizine, bepidril, fluspirilene, fendiline, carbon dioxide, nitric oxide, nicorandil, isosorbide dinitrate, isosorbide mononitrate, sumatriptan, zolmitriptan, naratriptan, rizatriptan, alotriptan, eletriptan, frovatriptan, α1-adrenergic receptor ligands, α1-adrenergic receptor agonists, α1-adrenergic receptor antagonists, α2-adrenergic receptor ligands, α2-adrenergic receptor agonists, α2-adrenergic receptor antagonists, β-adrenergic receptor ligands, β-adrenergic receptor agonists, β-adrenergic receptor antagonists, sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan, bosentan, macitentan, tezosentan, magnesium sulfate, papaverine, nafronyl, and hexobendine. ### Claim 23 (depends on 20) The method of claim 20, wherein the method further comprises circulating a perfusate through the brain of the invention.